Carbamazepine Labeling To Advise Genetic Screen To Avoid Side Effect
Executive Summary
Labeling for carbamazepine drugs will be revised to recommend patients of Asian descent be genetically screened prior to starting therapy to help identify those at an increased risk of a serious side effect, FDA announced Dec. 12